Drug intelligence / Profile preview

nafarelin

Development stage: Approved
Lead developer: Pfizer
Modality: Peptides, Small Molecules
Administration: Intranasal

Overview

Nafarelin is a synthetic gonadotropin-releasing hormone (GnRH) agonist administered as a nasal spray. It works by initially stimulating the release of pituitary gonadotropins (LH and FSH), followed by suppression with continued use, leading to decreased sex hormone levels. This mechanism makes it effective for treating endometriosis in adult women by reducing estrogen levels and for managing central precocious puberty (CPP) in children by slowing sexual development and bone growth.

Brand names: Synarel
Other names: nafarelinnafarelin base

Targets

GnRHR (Gonadotropin-releasing hormone receptor)

Beyond the preview

Go deeper on nafarelin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on nafarelin.

Explore the full profile